S
SLAYBACK PHARMA INDIA LLP
Slayback is a New-Jersey based pharmaceutical company focused on the development of complex generic and specialty pharmaceutical products with a team of 90 employees and operations in the U.S. and India. Since its inception in 2011, Slayback has demonstrated a spectacular track record of numerous sole first-to-file ANDAs, 505(b)(2)s and complex generic filings, approvals and launches.
Country/Area ：India
Company Email ：rahul@slayback-pharma.com
Industry ：Vehicles & TransportationRetailDrug Stores & PharmaciesElectronicsMachinery
Company website ：*****
Company phone ：(609) 945-3443
Established ：2011
Company Revenue ：$17,318,000
Number of employees ：88
SIC Code ：28283
NAICS Code ：32325
Main Products ：FIRST ® – OmeprazoleAzurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During ManufacturingFIRST ® – BLM MouthwashAZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF MYHIBBIN™ (mycophenolate mofetil oral suspension)Medical InformationFIRST ® – LansoprazoleAzurity Solutions – Patient DirectFIRST ® – ProgesteroneFIRST ® – PantoprazoleEDARBYCLOR ®Compounding KitsManagement TeamPatents & TrademarksFIRST ® – MetronidazoleBoard of Directors
Company News
Azurity Pharmaceuticals Acquires Slayback Pharma
Sep 27, 2023
WOBURN, Ma., Sept. 27, 2023 /PRNewswire/ -- Azurity Pharmaceuticals, Inc. ("Azurity") is pleased to announce the closing of its acquisition of Slayback Pharma LLC ("Slayback") today from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is...
Sep 27, 2023
Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Product in the U.S.Apr 26, 2023
DUBLIN, April 26, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. (collectively "Endo") have executed an agreement with Slayback Pharma LLC to distribute Slayback's Prevduo™ (neostigmine...
Apr 26, 2023Dr Reddy's Laboratories inks licensing pact with US' Slayback PharmaJul 30, 2022
Dr Reddy's Laboratories on Saturday said it has entered into a pact with US-based Slayback Pharma to acquire rights of a medication to relieve redness of the eyes
Jul 30, 2022Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.Jul 29, 2022
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Alcon--Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC.
Jul 29, 2022Slayback Appoints Pete Meyers as Chief Financial OfficerJun 25, 2021
PRINCETON, N.J., June 25, 2021 /PRNewswire/ -- Slayback Pharma LLC, a Princeton, NJ based specialty pharmaceutical company, announced today the appointment of Pete A. Meyers as its Chief Financial Officer. Pete has nearly three decades of rich experience in the pharmaceutical industry...
Jun 25, 2021Web Summary
Q1: What is the company name and its location?
A1: The company name is Azurity Pharmaceuticals, Inc., and it is located in Woburn, Massachusetts.
Q2: What type of products does the company specialize in developing?
A2: Azurity specializes in providing innovative, high-quality medicines that serve overlooked patients. They develop dose-form innovations of established medicines for patients who have unmet needs.
Q3: What are some of the therapeutic areas targeted by the company's products?
A3: Azurity offers an ever-expanding portfolio of products targeting key therapeutic areas, including cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective, and oncology medicines.
Q4: What is the name of the first and only FDA-approved prefilled testosterone cypionate injection developed by the company?
A4: The name of the product is Azmiro TM (testosterone cypionate) injection for intramuscular use, CIII.
Q5: What is the name of the first and only nilotinib with no mealtime restrictions approved by the FDA?
A5: The name of the product is Danziten TM (nilotinib) tablets.
Q6: What is the company's mission in developing innovative medicines for patients who have unmet needs?
A6: Azurity develops dose-form innovations of established medicines to serve overlooked patients, providing innovative, high-quality medicines that benefit millions of people.
Q7: How can healthcare professionals stay updated on new products and resources from Azurity?
A7: Healthcare professionals can sign up for email updates on the company's website to receive information about AZURITY and new hypothyroidism resources.
Q8: What is the purpose of the FIRST Kits program offered by the company?
A8: The FIRST Kits program provides innovative, high-quality medicines that serve overlooked patients, offering dose-form innovations of established medicines for patients who have unmet needs.
A1: The company name is Azurity Pharmaceuticals, Inc., and it is located in Woburn, Massachusetts.
Q2: What type of products does the company specialize in developing?
A2: Azurity specializes in providing innovative, high-quality medicines that serve overlooked patients. They develop dose-form innovations of established medicines for patients who have unmet needs.
Q3: What are some of the therapeutic areas targeted by the company's products?
A3: Azurity offers an ever-expanding portfolio of products targeting key therapeutic areas, including cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective, and oncology medicines.
Q4: What is the name of the first and only FDA-approved prefilled testosterone cypionate injection developed by the company?
A4: The name of the product is Azmiro TM (testosterone cypionate) injection for intramuscular use, CIII.
Q5: What is the name of the first and only nilotinib with no mealtime restrictions approved by the FDA?
A5: The name of the product is Danziten TM (nilotinib) tablets.
Q6: What is the company's mission in developing innovative medicines for patients who have unmet needs?
A6: Azurity develops dose-form innovations of established medicines to serve overlooked patients, providing innovative, high-quality medicines that benefit millions of people.
Q7: How can healthcare professionals stay updated on new products and resources from Azurity?
A7: Healthcare professionals can sign up for email updates on the company's website to receive information about AZURITY and new hypothyroidism resources.
Q8: What is the purpose of the FIRST Kits program offered by the company?
A8: The FIRST Kits program provides innovative, high-quality medicines that serve overlooked patients, offering dose-form innovations of established medicines for patients who have unmet needs.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
